Neuronostics

About Neuronostics

Neuronostics aims to transform epilepsy care by leveraging advanced digital analysis of background EEG. Their mission is to improve efficiency for clinicians and enable earlier, more accurate diagnoses, ultimately enhancing neurological care with digital biomarkers.

Products & Services

BioEP™:An advanced solution that evolves traditional EEG by reducing its limitations, using biomarkers to support epilepsy diagnosis, making diagnostics more efficient, and improving patient outcomes.

EEG Reading:A service focused on the analysis and interpretation of EEG data to aid in neurological assessments.

Specialties

Digital Biomarkers EEG Analysis Epilepsy Diagnosis

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Prize/Grant (Shark Tank Competition) T: - FT: Prize/Grant (Shark Tank Competition)	A: 125000 MR: - FA: $125,000 FAN: 125000	D: 2024-09-30 FD: 2024-09-30	1 investors

Prize/Grant (Shark Tank Competition) Latest

2024-09-30

$125K

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Anne Hyland

NED, Board chair

C

Charlie Alvarez

NED Director

D

David Buller

Investor Director

R

Richard Haycock

investor director

J

John Terry

Co-Founder and Managing Director

W

Wessel Woldman

Co-Founder and Scientific Director

View 17 more team members with Pro

Unlock Full Team Directory

Recent News

Neuronostics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised